The Challenge: Frequent Intravitreal Injections Retinal disorders, including choroidal neovascularization, diabetic retinopathy, and age-related macular degeneration, can cause irreversible loss of vision. The therapeutics that
Bacterial resistance in ocular microbial disease is a recurring problem. Successive generations of antibiotic exposure establish mutations, and emergent multidrug-resistant species render existing antimicrobial treatments
The Challenge: Treating Blepharitis and the Absence of Approved Ophthalmic Therapy Blepharitis is a chronic inflammation of the eyelids in which the eyelids become red,
The Challenge: Glaucoma and the Limits of Conventional Brinzolamide Eye Drops Glaucoma is one of the leading causes of blindness among the elderly. It is
Selecting drug delivery routes is one of the earliest decisions that can shape a drug development program. The route affects formulation strategy, exposure, patient use,
The Problem: UV Exposure and Ocular Tissue Damage Ultraviolet radiation is absorbed by multiple structures of the eye and is correlated with a range of
The Challenge: Dry Eye and the Limits of Artificial Tears Dry eye disease is characterized by inflammation, loss of tear film integrity, and reduced tear
Outsourcing formulation development is a critical decision point for biotech and pharmaceutical teams moving from discovery into development. It affects timelines, risk, data quality, and
Bedford, MA – Jun 4, 2024. Symphony Therapeutics, a subsidiary of Integral BioSystems, will showcase its innovative Lubricating Ocular Bandage™ at the 27th Annual TechConnect
Bedford, MA – Jun 4, 2024. Symphony Therapeutics, a subsidiary of Integral BioSystems, is set to revolutionize ophthalmic drug delivery with its OcuHeal™ LNP platform.